) recently joined forces with
) for the advancement of its spinal muscular atrophy (SMA)
The SMA program was originally in-licensed from Families of SMA
(FSMA). The lead candidate in this program, RG3039, is in a phase
I trial - the first two arms of this trial will be completed by
Repligen following which Pfizer will take over the development of
SMA is a genetic disease that presents early in life. According
to The SMA Trust, one child out of every 6,000 births is affected
Repligen has Orphan Drug and Fast Track status for RG3039 in the
US as well as Orphan Medicinal Product designation in the EU.
Terms of the Deal
Under this deal, Repligen could receive up to $70 million from
Pfizer, including an upfront payment of $5 million. The balance
$65 million would be received on the achievement of future
milestones. Further, royalty payments will be made by Pfizer on
sales of SMA compounds developed under the agreement.
BIOMIMETIC THER (BMTI): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
REPLIGEN (RGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
This deal is a major positive for Repligen. It not only provides
it with a strong development partner like Pfizer, it also
provides the company with funds in the form of upfront, milestone
and other payments. Repligen's strategy is to use its internal
efforts for the growth of bioprocessing business and seek
external partners for its therapeutic development programs.
Meanwhile, the deal is in line with Pfizer's strategy of
expanding its orphan drug segment.
We currently have a Neutral recommendation on Repligen. The stock
carries a Zacks #1 Rank (Strong Buy).
BioMimetic Therapeutics Inc.
) is another player which carries a Zacks #1 Rank.